WEEKLY e-ALERT [ BASIC EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
  • Industry News
  • Lilly Expands China Partnership With Innovent in New Global Oncology and Immunology Deal Worth Up to $8.5B(2/9/2026) (Premium)
  • BioKangtai Cancels Planned Vaccine Joint Venture With AstraZeneca in China(2/9/2026) (Premium)
  • Cascade Raises $72M to Advance MASH, Obesity and Diabetes Pipeline(2/10/2026) (Premium)
  • Hengrui and Kailera Advance Obesity Therapy After Encouraging Mid-Stage China Results(2/10/2026) (Premium)
  • Insilico and CMS Partner on AI-Driven CNS and Autoimmune Drug Programs(2/10/2026) (Premium)
  • AstraZeneca's China Business Hits New Heights as Record Revenue Boosts Emerging Markets Growth(2/10/2026) (Premium)
  • Sanofi Backs GluBio's Molecular Glue Pill for Sickle Cell Disease(2/11/2026) (Premium)
  • Madrigal Expands MASH Pipeline with Six siRNA Programs from China's Ribo Life Science(2/11/2026) (Premium)
  • TenNor Therapeutics Files for Hong Kong IPO as Dual-Core Antibiotic Pipeline Advances(2/11/2026) (Premium)
  • Regend Raises CNY 350M Series C to Advance Cell-Based Organ Regeneration Pipeline(2/11/2026) (Premium)
  • UniXell Raises Over CNY 50M in Series A+ to Advance Stem Cell Therapy Pipeline(2/12/2026) (Premium)
  • Gilead Acquires Global Rights to Genhouse Oral Cancer Drug With $80 Million Upfront(2/13/2026) (Premium)
  • Salubris Files Hong Kong IPO to Expand Cardiovascular-Kidney-Metabolic Pipeline(2/13/2026) (Premium)
  • VivaVision Files Hong Kong IPO to Fund Late-Stage Ophthalmology Programs(2/13/2026) (Premium)
  • ProteLight Pharmaceuticals Files Hong Kong IPO application(2/13/2026) (Premium)
  • Shenzhen Immunofoco Biotechnology files Hong Kong IPO application(2/13/2026) (Premium)
  • Recordati to Withdraw from China After Rare Disease Portfolio Underperforms(2/14/2026) (Premium)
  • Home | Contact Us | Subscribe
  • © Wicon International Group